Back to Search
Start Over
LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
- Source :
- Annals of Oncology. 32:S1316-S1317
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
- Subjects :
- Oncology
medicine.medical_specialty
business.industry
medicine.medical_treatment
Binimetinib
Ipilimumab
Hematology
Immunotherapy
law.invention
chemistry.chemical_compound
chemistry
Randomized controlled trial
law
Internal medicine
Encorafenib
medicine
In patient
Target therapy
Nivolumab
business
medicine.drug
Subjects
Details
- ISSN :
- 09237534
- Volume :
- 32
- Database :
- OpenAIRE
- Journal :
- Annals of Oncology
- Accession number :
- edsair.doi...........a3a2c3ae90cb141381009d84df162426
- Full Text :
- https://doi.org/10.1016/j.annonc.2021.08.2118